Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Apotex has acquired Cumberland Pharmaceuticals, a pharmacy business in Tennessee, for $100 million. Cumberland Pharmaceuticals develops and commercializes FDA-approved specialty medicines, including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, with headquarters in Nashville, TN. Apotex acquisitions are aimed at expanding a U.S. branded specialty medicines platform by integrating Cumberland’s commercial products into Apotex’s affiliate business. The healthcare M&A is structured as a divestiture acquisition via an asset purchase agreement, with Apotex paying cash at closing and Cumberland retaining ifetroban product candidates and Cumberland Emerging Technologies.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026